IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gerald W. FISCHER et al. Confirmation No.: 5776

Patent No.: 6,939,543 B2 Application No.: 09/893,615

Patent Date: September 6, 2005 Filing Date: June 29, 2001

For: OPSONIC AND PROTECTIVE MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR LIPOTEICHOIC ACID OF GRAM POSITIVE BACTERIA

Attorney Docket No.: 103901-4199

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 C.F.R. §§ 1.322 and 1.323

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Title Page:

Item (56) **References Cited**, please add the following:

-- 2003/0235578 A1 12/2003 Stinson et al. 424/130.1
2004/0013673 A1 01/2004 Fischer et al.....424/164.1
2004/0052779 A1 03/2004 Stinson et al. .....424/130.1 --

Item (56) OTHER PUBLICATIONS, please add the following:

-- Yuji, Y. et al., Men'eki Arerugi, Vol. 13(2), pages 50-51, 1994, Figure 4, (abstract only).*

Dale et al., Journal of Infectious Diseases, Vol. 169, pages 319-323, 1994, Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid.*

Ichiman, Y. et al., Journal of Applied Bacteriology, Vol. 51, pages 229-241, 1981.*

Sutcliffe, Iain C., Journal of Bacteriology, Vol. 173(22) Nov. 1991, pages 7065-7069.*

Remington's Pharmaceutical Sciences, pp. xv-xvi (A. Gennaro, ed., Mark Publishing Co. 1990).

Sambrook et al., Molecular Cloning, pp. xi-xxxviii (Cold Spring Harbor Laboratory, 1989).

Short Protocols in Molecular Biology, pp. iii-xvi (F. Ausubel et al., eds., Greene Publishing Assoc., 1989). --

Support for the addition of the above references appears on patentees' PTO-1449 filed January 7, 2005, which was considered and initialed by the Examiner on February 15, 2005, and on pages 2-4 of the PTO-892, part of Paper No. 14, copies of which are attached hereto.

Page 2, Column 1:

"Fiedel" reference, after "Abstracts of" change "teh" to -- the --.

Page 2, Column 2:

"Gazmuri et al" reference, after "antibody" change "from" to -- for --.

"Archibald, Ar et al" reference, after "Archibald" change "Ar" to -- AR --.

"Brock, JH" reference, change "*Staphylocccal*" to -- *Staphylococcal* --.

"Karakawa, WW et al" reference, change "*Staphylococococcus*" to -- *Staphylococcus* --.

"Naumova, IB et al." reference, change "occurance" to -- occurrence --.

Page 3, Column 2:

"West, Timothy E. et al." reference, change "Immunogloublin" to -- Immunoglobulin --.

Page 4, Column 1:

"Cieslak et al." reference, change "*Reasearch*" to -- *Research* --.

Page 4, Column 2:

"Fischer et al." reference (first occurrence), change "Defences" to -- Defenses --.

"Fischer et al." reference (second occurrence), change "Globuline" to -- Globulin --.

Page 5, Column 1:

"Modun et al." reference (fourth occurrence), change "Treansferrin" to -- Transferrin --.

"NIH Consensus Conference" reference, change "Treament" to -- Treatment --.

Page 5, Column 2:

"Smith et al." reference, change "Curtured on Human Perioneal" to -- Cultured on Human Peritoneal --.

"Wheat" reference, change "Chormatographic" to -- Chromatographic --.

Page 6, Column 1:

"Williams et al." reference, change "*Mircrobiol.*" to -- *Microbiol.* --.

The above requested changes are to correct errors of a clerical or typographical nature and do not involve changes that would constitute new matter or require reexamination.

A fee of $100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

12/19/05

Date

Jeffrey A. Wolfson (Reg. No. 42,234

WINSTON & STRAWN LLP
Customer No. 28765

202-282-5770

DEC 2 1 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.: 6,939,543 B2
DATED: September 6, 2005
INVENTORS: Fischer et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:
Item (56) **References Cited**, add the following:

-- 2003/0235578 A1	12/2003	Stinson et al.	424/130.1
2004/0013673 A1	01/2004	Fischer et al.	424/164.1
2004/0052779 A1	03/2004	Stinson et al.	424/130.1 --

OTHER PUBLICATIONS, add the following:
--Yuji, Y. et al., Men'eki Arerugi, Vol. 13(2), pages 50-51, 1994, Figure 4, (abstract only).*
Dale et al., Journal of Infectious Diseases, Vol. 169, pages 319-323, 1994, Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid.*
Ichiman, Y. et al., Journal of Applied Bacteriology, Vol. 51, pages 229-241, 1981.*
Sutcliffe, Iain C., Journal of Bacteriology, Vol. 173(22) Nov. 1991, pages 7065-7069.* --
Remington's Pharmaceutical Sciences, pp. xv-xvi (A. Gennaro, ed., Mark Publishing Co. 1990).
Sambrook et al., Molecular Cloning, pp. xi-xxxviii (Cold Spring Harbor Laboratory, 1989).
Short Protocols in Molecular Biology, pp. iii-xvi (F. Ausubel et al., eds., Greene Publishing Assoc., 1989). --

"Fiedel" reference, after "Abstracts of" change "teh" to -- the --.
"Gazmuri et al" reference, after "antibody" change "from" to -- for --.
"Archibald, Ar et al" reference, after "Archibald" change "Ar" to -- AR --.
"Brock, JH" reference, change "*Staphylocccal*" to -- *Staphylococcal* --.
"Karakawa, WW et al" reference, change "*Staphylococcoccus*" to -- *Staphylococcus* --.
"Naumova, IB et al." reference, change "occurance" to -- occurrence --.
"West, Timothy E. et al." reference, change "Immunogloublin" to -- Immunoglobulin --.
"Cieslak et al." reference, change "*Reasearch*" to -- *Research* --.
"Fischer et al." reference (page 4, first occurrence), change "Defences" to -- Defenses --.
"Fischer et al." reference (page 4, second occurrence), change "Globuline" to -- Globulin --.
"Modun et al." reference (page 5, fourth occurrence), change "Treansferrin" to -- Transferrin --.
"NIH Consensus Conference" reference, change "Treament" to -- Treatment --.

WINSTON & STRAWN LLP
Patent Department
1700 K Street, N.W.
Washington, D.C. 20006-3817

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.: 6,939,543 B2
DATED: September 6, 2005
INVENTORS: Fischer et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

"Smith et al." reference, change "Curtured on Human Perioneal" to -- Cultured on Human Peritoneal --.
"Wheat" reference, change "Chormatographic" to -- Chromatographic --.
"Williams et al." reference, change "*Mircrobiol.*" to -- *Microbiol.* --.

WINSTON & STRAWN LLP
Patent Department
1700 K Street, N.W.
Washington, D.C. 20006-3817

Remington's Pharmaceutical Sciences, pp. xv-xvi (A. Gennaro, ed., Mark Publishing Co. 1990).

Sambrook et al., Molecular Cloning, pp. xi-xxxviii (Cold Spring Harbor Laboratory, 1989).

Short Protocols in Molecular Biology, pp. iii-xvi (F. Ausubel et al., eds., Greene Publishing Assoc., 1989). --

Support for the addition of the above references appears on patentees' PTO-1449 filed January 7, 2005, which was considered and initialed by the Examiner on February 15, 2005, and on pages 2-4 of the PTO-892, part of Paper No. 14, copies of which are attached hereto.

Page 2, Column 1:

"Fiedel" reference, after "Abstracts of" change "teh" to -- the --.

Page 2, Column 2:

"Gazmuri et al" reference, after "antibody" change "from" to -- for --.

"Archibald, Ar et al" reference, after "Archibald" change "Ar" to -- AR --.

"Brock, JH" reference, change "*Staphylocccal*" to -- *Staphylococcal* --.

"Karakawa, WW et al" reference, change "*Staphylococococcus*" to -- *Staphylococcus* --.

"Naumova, IB et al." reference, change "occurance" to -- occurrence --.

Page 3, Column 2:

"West, Timothy E. et al." reference, change "Immunogloublin" to -- Immunoglobulin --.

Page 4, Column 1:

"Cieslak et al." reference, change "*Reasearch*" to -- *Research* --.

Page 4, Column 2:

"Fischer et al." reference (first occurrence), change "Defences" to -- Defenses --.

"Fischer et al." reference (second occurrence), change "Globuline" to -- Globulin --.

Page 5, Column 1:

"Modun et al." reference (fourth occurrence), change "Treansferrin" to -- Transferrin --.

"NIH Consensus Conference" reference, change "Treament" to -- Treatment --.

Page 5, Column 2:

"Smith et al." reference, change "Curtured on Human Perioneal" to -- Cultured on Human Peritoneal --.

"Wheat" reference, change "Chormatographic" to -- Chromatographic --.

Page 6, Column 1:

"Williams et al." reference, change "*Mircrobiol.*" to -- *Microbiol.* --.

The above requested changes are to correct errors of a clerical or typographical nature and do not involve changes that would constitute new matter or require reexamination.

A fee of $100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

12/19/05

Date

Jeffrey A. Wolfson (Reg. No. 42,234

WINSTON & STRAWN LLP
Customer No. 28765

202-282-5770

U.S. PATENT DOCUMENTS

4,425,330	A		1/1984	Norcross et al.	424/92
4,460,575	A		7/1984	d'Hinterland	424/92
4,482,483	A		11/1984	Curry et al.	260/112
4,596,769	A	*	6/1986	Shockman et al.	435/7
4,719,290	A		1/1988	Curry et al.	530/387
4,732,757	A		3/1988	Stolle et al.	424/87
4,744,982	A	*	5/1988	Hunter et al.	424/142.1
4,761,283	A	*	8/1988	Anderson	424/194.1
4,789,735	A		12/1988	Frank et al.	530/395
4,830,852	A		5/1989	Marburg et al.	424/85.8
4,888,279	A	*	12/1989	Zeiger	435/7.8
4,902,616	A		2/1990	Fournier et al.	435/101
4,954,449	A	*	9/1990	Hunter et al.	530/388.15
4,965,068	A	*	10/1990	Stephan et al.	424/87
RE33,565	E	*	4/1991	Stolle et al.	424/87
5,034,515	A		7/1991	Proctor	536/1.1
5,043,267	A	*	8/1991	Richards	435/7.31
5,055,455	A		10/1991	Pier et al.	514/54
5,069,896	A	*	12/1991	Rogers et al.	424/65
5,153,312	A		10/1992	Porro	530/405
5,175,096	A		12/1992	Höök et al.	435/69.1
5,354,654	A		10/1994	Ligler et al.	435/5
5,440,014	A		8/1995	Höök et al.	530/326
5,505,945	A		4/1996	Gristina et al.	424/164.1
5,530,102	A		6/1996	Gristina et al.	530/391.1
5,538,733	A		7/1996	Emery et al.	424/422
5,545,721	A		8/1996	Caroll et al.	530/391.7
5,571,511	A		11/1996	Fischer	
5,585,098	A	*	12/1996	Coleman	424/157.1
5,624,904	A		4/1997	Krieger et al.	
5,652,217	A		7/1997	Höök et al.	514/12
5,707,627	A	*	1/1998	Gristina et al.	424/64.1
5,770,208	A	*	6/1998	Fattom et al.	424/197.11
5,840,846	A		11/1998	Höök et al.	530/350
5,851,535	A		12/1998	Jolivet-Reynaud	
5,955,074	A	*	9/1999	Fischer	424/130.1
5,955,078	A		9/1999	Burnham et al.	424/190.1
6,080,407	A	*	6/2000	Bucala et al.	424/158.1
6,168,790	B1	*	1/2001	Ulevitch et al.	424/150.1
6,194,161	B1	*	2/2001	Fattom et al.	435/7.1
6,294,177	B1	*	9/2001	Fattom	424/243.1
RE37,525	E	*	1/2002	Prince et al.	424/45
6,355,625	B1	*	3/2002	Pavliak et al.	514/54
6,365,156	B1	*	4/2002	Lee	424/147.1
6,372,897	B1	*	4/2002	Colette	536/23.1
6,610,293	B1	*	8/2003	Fischer et al.	424/133.1
2002/0031528	A1	*	3/2002	Fattom	424/243.1
2002/0102262	A1	*	8/2002	Hook et al.	424/150.1
2003/0103969	A1	*	6/2003	Ulevitch et al.	424/140.1
2003/0119101	A1	*	6/2003	Burnie et al.	435/69.1

FOREIGN PATENT DOCUMENTS

WO	WO 90/03398		4/1990	
WO	WO 93/09811		5/1993	
WO	93/09811	*	5/1993	A61K/39/02
WO	WO 93/17044		9/1993	
WO	WO 93/19373		9/1993	
WO	93/19373	*	9/1993	G01N/33/569
WO	WO 94/11026		5/1994	
WO	WO 96/09321		3/1996	
WO	96/23896	*	8/1996	C12P/19/44
WO	WO 96/39518		12/1996	
WO	WO 97/26010		7/1997	

OTHER PUBLICATIONS

Fiedel, BA et al, Abstracts of teh Annual Meeting of the American Society for Microbiology, vol. 72, p. 104, 1972 (abstract only).*

Stashenko, P et al, Archives of Oral Biology, vol. 31(7), pp. 455–461, 1986 (abstract only).*

Wergeland, HI et al, Journal of Clinical Microbiology, vol. 27(6), pp. 1286–1291, 1989, (abstract only).*

Gazmuri, et al, The New England Journal of Medicine,Jul. 25, 1991, vol. 325(4), pp. 279–283 "The Ha–1a monoclonal antibody from gram negative sepsis (correspondence)".*

Peake, S, Anaesth. Intens. Care, 1993, vol. 21, pp. 739–751, Monoclonal antibodies–immunotherapy for the critically ill.*

Lehner,T. Current Opinion in Immunology, vol. 1(3), pp. 462–466, 1989.*

Archibald, AR et al, Nature–New Biology, Jan. 3, 1973, vol. 241(105), pp. 29–31, Molecular arrangement of teichoic acid in the cell wall of *Staphylococcus lactis*.*

Brock, JH, Vaccination of the bovine against *Staphylocccal mastitis* with special reference to teichoic acid antibodies and the virulence of *S.aureus*, 1972–1973, publ. 1975, Index to Theses, vol. 23, p. 101, Reading University, citation only.*

Chugh, TD et al, Infection and Immunity, Feb. 1990, vol. 58(2), pp. 315–319, Feb. 1990, Adherence of *Staphylococcus epidermidis* to Fibrin–Platelet clots in vitro mediated by lipoteichoic acid.*

Ginsburg, I et al, Inflammation, vol. 12(6), 1988, Lipoteichoic acid–antilipoteichoic acid complexes induce superoxide generation by human neutrophils.*

Karakawa, WW et al, Journal of Immunology, vol. 114(1pt2), pp. 310–315, Jan. 1975, Immunochemistry of an acidic antigen isolated from a *Staphylococcus aureus*.*

Klesius, PH et al, Canadian Journal of microbiology, Jun. 1974, vol. (20)6, pp. 853–859, Human antibody response to a group A streptococcal teichoic acid.*

Mancuso, G et al, Infection and Immunity, vol. 62(4), pp. 1470–1473, Apr. 1994, Anti–lipoteichoic acid antibodies enhance release of cytokines by monocytes sensitized with lipoteichoic acid.*

Naumova, IB et al, Archives of microbiology, May 1980, vol. 126(1), pp. 71–75, The occurance of teichoic acids in streptomycetes (abstract only).*

Ohshima, Y et al, Staphylococcal lipoteichoic acid, a potent simulant of immune cell porliferation, maturation and activation, Zentralblatt Fur Bakteriologie—supplemnet, 1994, issue 26, pp. 437–439.*

Prokop, O et al, ACTA biologica et medica Germanica, 1970, vol. 24(3), pp. 19–23 (German article), English title and Descriptors, The therapeutic use of anti–A–HP in the treatment of staphylococcal skin diseases as a result of the affinity of the hetero.*

Stashenko, P et al, Archives of oral biology, 1986, vol. 31(7), pp. 455–461, Effect of monoclonal antibodies against lipoteichoic acid from the oral bacterium *Streptococcus mutans* on its adhesin and plaque–accumulation in vitro.*

Wu, TC et al, Journal of Bacteriology, Nov. 1971, vol. 108(2), pp. 874–884, Chemical characterization of anew surface antigenic polysaccharide from a mutant of *Staphylococcus aureus*.*

PCT International Search Report, dated Sep. 9, 2003.

Borrebaeck, *Antibody Engineering*, 2nd Ed., Oxford University Press, NY (1995).

Carruthers and Kabat, Mediation of Staphylococcal Adherence to Mucosal Cells by Lipoteichoic Acid, *Infect Immun.* 40:444–46 (1983).

Add: 2003/0235578 A1 12/2003 Stinson et al. 424/130.1
2004/0013673 A1 01/2004 Fischer et al. 424/164.1
2004/0052779 A1 03/2004 Stinson et al. 424/130.1
(See PTO-1449 Jan. 7, 2005)

Current Methods in Hybridoma Formation, Bartal et al. (ed.) *Methods of Hybridoma Formation*, Humana Press, Clifton, New Jersey (1987).

De Kimpe et al., The Cell Wall Components Peptidoglycan and Lipoteichoic Acid From *S. aureus* Act in Synergy to Cause Shock and Multiple Organ Failure, *Proc. Nat. Acad. Sci. (USA)*92:10359–63 (1995).

Fischer et al., Improved Preparation of Lipoteichoic Acids, *Eur. J. Biochem.* 133:523–30 (1983).

Fournier, *Staphylococcus aureus, Vaccines and Immunotherapy*, Ch. 13, pp. 166–177 (1991).

Gonzalez and Hill, The Current Status of Intravenous Gamma–globulin Use in Neonates, *J. Ped. Infect. Dis.* 8:315–22 (1989).

Green et al., Antigen–Specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs, *Nat. Genet.* 7:13–21 (1994).

Hancock, Bacterial Cell Surface Carbohydrates: Structure and Assembly, *Biochem. Soc. Trans.* 25:183–87 (1997).

Jendeberg et al., Engineering of Fc_1 and Fc_3 From Human Immunoglobulin G to Analyse Subclass Specificity for Staphylococcal Protein A, *J. Immunol. Methods* 201:25–34 (1997).

Lee, The Prospects for Developing a Vaccine Against *Staphylococcus aureus, Trends in Micro.* 4:162–66 (1996).

LoBuglio et al., Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response, *P.N.A.S.* 86:4220–24 (1989).

Low et al., Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain, *J Mol Biol* 260:359–68 (1996).

McDermid et al., A Porcine Model of *Staphylococcus epidermidis* Catheter–Associated Infection, J. *Infect. Dis.* 168: 897–903 (1993).

Nealon and Mattingly, Role of Cellular Lipoteichoic Acids in Mediating Adherence of Serotype III Strains of Group B Streptococci to Human Embryonic, Fetal, and Adult Epithelial Cell, *Infect Immun.* 43:523–30 (1984).

Oshima et al., Comparison of Cell Wall Teichoic Acid Fractions Isolated from Three Different Encapsulated Strains of *Staphylococcus epidermidis, Ann. Microbiol.* 135:353–65 (1984).

Peterson et al., Effect of Protein A on Staphylococcal Opsonization, *Infection and Immunity* 15:760–64 (1977).

Peterson et al., Influence of Encapsulation on Staphylococcal Opsonization and Phagocytosis by Human Polymorphonuclear Leukocytes, *Infection and Immunity* 19:943–49 (1978).

Quie et al., Defective Phagocytosis of Staphylococci, *Ann. N. Y. Acad. Sci.* 236:233–43 (1974).

Romero–Vivas et al., Mortality Associated with Nosocomial Bacteremia due to Methicillin–Resistant *Staphylococcus aureus, Clin. Infect. Dis.* 21:1417–23 (1995).

Salton, The Bacterial Cell Envelope—A Historical Perspective, in J.–M. Ghuyson and R. Hakenbeck (Ed.), *Bacterial Cell Wall*, Elsevier Science BV, Amsterdam, pp. 1–22 (1994).

Schwab et al., Increased Adherence of *Staphylococcus aureus* From Cystic Fibrosis Lungs to Airway Epithelial Cells, *Am. Rev. Respir. Dis.* 148:365–69 (1993).

Shulman et al., A Better Cell Line for Making Hybridomas Secreting Specific Antibodies, *Nature* 276:269–70 (1978).

Takada et al., Molecular and Structural Requirements of a Lipoteichoic Acid From *Enterococcus hirae* ATCC 9790 for Cytokine–Inducing, Antitumor, and Antigenic Activities, *Infection and Immunity* 63:57–65 (1995).

Teti et al., Adherence of Group B Streptococci to Adult and Neonatal Epithelial Cells Mediated by Lipoteichoic Acid, *Infect Immun.* 55:3057–64 (1987).

Wagner et al., The Diversity of Antigen–Specific Monoclonal Antibodies from Transgenic Mice Bearing Human Immunoglobulin Gene Miniloci, *Eur J Immunol* 24:2672–81 (1994).

Wagner et al., Antibodies Generated from Human Immunoglobulin Miniloci in Transgenic Mice, *Nuc. Acids Res.* 22:1389–93 (1994).

Waldvogel, *Staphylococcus aureus* (Including Toxic Shock Syndrome), In Mandell, G.L. et al. (ed.) *Principles and Practices of Infectious Diseases, Third Edition*, Churchill Livingstone, New York, Ch. 173, pp. 1489–1510 (1990).

Winter et al., Making Antibodies by Phage Display Technology, *Annu. Rev. Immunol.* 12:433–55 (1994).

Endl, J. et al., "Chemical Composition and Structure of Cell Wall Teichoic Acids of Staphylococci," *Arch Microbiol*, vol. 135, 1983, pp. 215–223.

Espersen, F. et al., "Cross–Reactions Between *Staphylococcus epidermidis* and 23 Other Bacterial Species," *Acta path. microbial. scand.*, sect. B. vol. 89, 1981, pp. 253–260.

Naumova, I.B. et al., "The Occurrence of Teichoic Acids in Streptomycetes," *Arch. Microbiol.*, vol. 126, 1980, pp. 71–75.

Osland, Arve et al., "Immunochemical Analysis of the Teichoic Acid from *Staphylococcus simulans," Acta path. microbial. scand.*, Sect. B, vol. 88, 1980, pp. 121–123.

West, Timothy E. et al., "Detection of Anti–Teichoic Acid Immunogloublin G Antibodies in Experimental *Staphylococcus epidermidis* Endocarditis," *Infection and Immunity*, vol. 42, No. 3, 1983, pp. 1020–1026. Immunoglobulin

Kojima, Yoshifumi et al., "Antibody to the Capsular Polysaccharide/Adhesin Protects Rabbits against Catheter–Related Bacteremia Due to Coagulase–Negative Staphylococci," *J. of Infectious Diseases*, vol. 162, pp. 435–441 (1990).

Jackson, Dianne E. et al., "Monoclonal Antibodies to Immunodeterminants of Lipoteichoic Acids," *Infection and Immunity*, pp. 800–803, Mar. 1984.

Mancuso, Giuseppe et al., "Anti–Lipoteichoic Acid Antibodies Enhance Release of Cytokines by Monocytes Sensitized with Lipoteichoic Acid," *Infection and Immunity*, pp. 1470–1473, Apr. 1994.

Derwent English language abstract of EP 0 724 016 A1, Abstract No. 96–343531/199635.

Raynor, Robert H. et al., "Lipoteichoic Acid Inhibition of Phagocytosis of *Staphylococcus aureus* by Human Polymorphonuclear Leukocytes", *Clinical Immunology and Immunopathology*, vol. 19, pp. 181–189 (1981).

Ahmad et al., Sequential Release of Antigens from Chloroform–treated *Staphylococcus epidermidis*: Application Towards a Possible Vaccine, *J. App. Bacteriol.* 69:676–85 (1990).

Ahmed et al., Preparation and Efficacy of Staphylococcal Vaccine by Sequential Release of Antigen from Solvent Treated Bacteria, *Soc. Appl. Bacter.* 67: xv (1989).

Another Sepsis Drug Down—Immunex's TNF Receptor, *Biotechnology Newswatch*, A. McGraw–Hill Publication, pp. 2–3 (Oct. 4, 1993).

Baird–Parker, The Basis for the Present Classification of Staphylococci and Micrococci, Recent Advances in Staphylococcal Research, *Ann. N.Y. Acad. Sci.* 236: 7–14 (W. Yotis, ed. 1974).

Baker et al., Multicenter Trial of Intravenous Immunoglobulin (IVIG) to Prevent Late–Onset Infection in Preterm Infants: Preliminary Results, *Ped. Res.* 25:275A (1989).

Baker et al., Intravenous Immune Globulin for the Prevention of Nosocomial Infection in Low Birth Weight Neonates, *New Eng. J. Med.* 327: 213–19 (1992).

Bonnerjea et al., Protein Purification: The Right Step at the Right Time, *Biotechnology* 4:954–58 (1986).

Boslego et al., Gonorrhea Vaccines, In Vaccines and Immunotherapy, Chap. 17, Cryz ed., Pergamon Press, pp. 211–223 (1991).

Campbell, Monoclonal Antibodies and Immunosensor Technology, *Laboratory Techniques in Biochemistry and Molecular Biology* 23, Chapter 1, pp. 1–49 (1991).

Carozzi et al., Response of CAPD Patients with a High Incidence of Peritonitis to Intraperitoneal Immunoglobulin Therapy, *Trans. Am. Soc. Artif. Intern. Organs.* 34: 635–39 (1988).

Chugh et al., Adherence of *Staphylococcus epidermidis* to Fibrin–Platelet Clots In Vitro Mediated by Lipoteichoic Acid, *Infect. and Immun.* 58: 315–19 (1990).

Cieslak et al., Post-Immunization Antibodies to *S. epidermidis* are Broadly Reactive and Opsonic, *Ped Reasearch* 31: 275A (1992).

Clapp et al., Use of Intravenously Administered Immune Globulin to Prevent Nosocomial Sepsis in Low Birth Weight Infants: Report of a Pilot Study, *J. Pediatr.* 115: 973–78 (1989).

Clark et al., Opsonic Requirements of *Staphylococcus epidermidis, J. Med. Microbiol.* 22:1–7 (1986).

Clark et al., Opsonic Activity of Intravenous Immunoglobulin Preparations Against *Staphylococcus epidermidis, J. Clin. Pathol.* 39:856–60 (1986).

Dick et al., Glycoconjugates of Bacterial Carbohydrate Antigens, *Contrib. Microbiol & Immunol.* 10:48–114 (1989).

Doyle et al., Soluble Macromolecular Complexes Involving Bacterial Teichoic Acids, *J. Bacteriol.* 124: 341–47 (1975).

Ellis, New Technologies for Making Vaccines, In Vaccines, Chap. 29, W.B. Saunders Co., at 568–75 (Plotkin and Mortimer eds., 1988).

Espersen et al., Solid–Phase Radioimmunoassay for IgG Antibodies to *Staphylococcus epidermidis, Arch. Inter. Med.* 147:689–93 (1987).

Espersen et al., *Staphylococcus aureus*, in "Antigen Detection to Diagnose Bacterial Infections" vol. II, CRC Press Inc., at 127–34 (Kohler, ed., 1986).

Espersen et al., Enzyme–Linked Immunosorbent Assay for Detection of *Staphylococcus epidermidis* Antibody in Experimental *S. epidermidis* Endocarditis, *J. Clin. Microbiol.* 23: 339–42 (1986).

Etzioni et al., Effect of an Intravenous Gammaglobulin Preparation on the Opsonophagocytic Activity of Preterm Serum Against Coagulase–Negative Staphylococci, *Acta. Paediatr. Scand.* 79:156–61 (1990).

Fanaroff et al., A Controlled Trial of Intravenous Immune Globulin to Reduce Nosocomial Infections in Very Low Birth Weight Infants, *New Eng. J. Med.* 330: 1107–13 (1992).

Fattom et al., Synthesis and Immunologic Properties in Mice of Vaccines Composed of *Staphylococcus aureus* Type 5 and Type 8 Capsular Polysaccharides Conjugated to *Pseudomonas aeruginosa* Exotoxin A, *Infect. & Immun.* 58(7): 2367–74 (1990).

Fattom et al., Capsular polysaccharide serotyping scheme for *Staphylococcus epidermidis, J. Clin. Microbiol.* 30: 3270–73 (1992).

Fischer et al., Diminished Bacterial Defences with Intralipid, *Lancet* 2: 819–20 (1980).

Fischer et al., Directed Immune Globuline Enhances Survival in an Intralipid Induced Neonatal Model of Lethal *Staphylococcus epidermidis* Sepsis, *Ped. Res. Abstr.* Abstract No. 1670 (Apr. 1991).

Fischer et al., Therapeutic Uses of Intravenous Gammaglobulin for Pediatric Infections, *Ped. Clin. N. Amer.* 35: 517–33 (1988).

Fischer et al., Opsonic antibodies to *Staphylococcus epidermidis*: in vitro and in vivo studies using human intravenous immune globulin, *J. Inf. Dis.* 169: 324–29 (1994).

Fleer et al., Septicemia due to Coagulase–negative Staphylococci in a Neonatal Intensive Care Unit: Clinical and Bacteriological Features and Contaminated Parenteral Fluids as a Source of Sepsis, *Pediatr. Infect. Dis.* 2: 426–31 (1983).

Fleer et al., Opsonic Defense to *Staphylococcus epidermidis* in the Premature Neonate, *J. Infect. Dis.* 152: 930–37 (1985).

Freeman et al., Association of Intravenous Lipid Emulsion and Coagulase–negative Staphylococcal Bacteremia in Neonatal Intensive Care Units, *New Eng. J. Med.* 323: 301–08 (1990).

Gunn, Comparative Virulence of Human Isolates of Coagulase–Negative Staphylococci Tested in an Infant Mouse Weight Retardation Model, *J. Clin. Microbiol.* 27: 507–11 (1989).

Haque et al., IgM–Enriched Intravenous Immunoglobulin Therapy in Neonatal Sepsis, *AJDC* 142: 1293–96 (1988).

Harlow et al., Monoclonal Antibodies, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Chapter 6, 139–243 (1988).

Ichiman et al., Cross Protection of Mice with the Smith Diffuse Strain of *Staphylococcus aureus* versus a type la Strain of Group B Streptococci, *Can. J. Microbiol.* 28: 726–32 (1982).

Ichiman et al. , Induction of Resistance with Heat–Killed Unencapsulated Strains of *Staphylococcus epidermidis* Against Challenge with Encapsulated Strains of *Staphylococcus epidermidis, Microbiol. Immunol.* 33: 277–86 (1989).

Ichiman et al., Protective Antibodies in Human Sera Against Encapsulated Strains of *Staphylococcus epidermidis, J. App. Bacter.* 63: 165–69 (1987).

Ichiman et al., Relation of Human Serum Antibody Against *Staphylococcus epidermidis* Cell Surface Polysaccharide Detected by Enzyme–Linked Immunosorbent Assay to Passive Protection in the Mouse, *J. App. Bacter.* 71: 176–81 (1991).

Ichiman et al., Monoclonal IgM Antibody Protection in Mice Against Infection with an Encapsulated Strain of *Staphylococcus epidermidis, Can. J. Microbiol.* 37: 404–07 (1991).

Johnsen et al., Studies on Polysaccharide C of *Staphylococcus epidermidis*, Acta Path. Microb. 83: 226–34 (1975).

Klein, From Harmless Commensal to Invasive Pathogen, *New Eng. J. Med.* 323: 339–40 (1990).
Kotani et al., Immunoadjuvant Activities of the Enzymatic Digests of Bacterial Cell Walls Lacking Immunoadjuvancy by Themselves, *Biken Journal* 20: 87–90 (1977).
Lamperi et al., Intraperitoneal Immunoglobulin (Ig) Treatment in Prophylaxis of Bacterial Peritonitis in CAPD, *Biomat., Art. Cells, Art. Org.* 15: 151–59 (1987).
Losnegard et al., Immunochemical Studies on Polysaccharides from *Staphylococcus epidermidis, Acta Path. Microbiol. Scand.* 58: 493–500 (1963).
Modun et al., A Preparation of *Staph. epidermidis* Vaccine by Enzymatic Digestion of Bacterial Cells, *J. Appl. Bacteriol.* 67:xv–xvi (1989).
Modun et al., Extraction by Immune Complexing of Protective Antigens of *Staphylococcus epidermidis*; Application Towards Vaccine Preparation, *J. Appl. Bacteriol.* 67: xvi (1989).
Modun et al., Cell Envelope Proteins of *Staphylococcus epidermidis* Grown in Vivo in a Peritoneal Chamber Implant, *Infect. & Immun.* 60: 2551–53 (1992).
Modun et al., Staphylococci Express a Receptor for Human Treansferrin: Identification of a 42–Kilodalton Cell Wall Transferrin–Binding Protein, *Infect & Immun.* 62: 3850–58 (1994).
Naumova et al., The Occurrence of Teichoic Acids in Streptomycetes, Abstract No. 3555r, *Chem. Abstracts* 93:342 abstract 3555r (1980).
NIH Consensus Conference, Intravenous Immunoglobulin: Prevention and Treament of Disease, *JAMA* 264: 3189–93 (1990).
Niizuma, Passive Protective Activities of Specific Human Immunoglobulin Against Strain ST67P of *Staphylococcus hyicus* Extracted from Pooled Human Sera, *Chem. Abstracts* 115:181022v at 713 (1990).
Niizuma, Passive Protection Activities of Specific Human Immunoglobulin Against Strain ST67P of *Staphylococcus hyicus* Extracted from Pooled Human Sera, *St. Marianna Med. J.* 18:940–46 (1990) (original, translation, and certificate of translation).
Oeding et al., Classification of Coagulase–Negative Staphylococci in the Diagnostic Laboratory, *ACTA Path. Microbiol. Scand.* 85: 136–40 (1977).
Osland et al., Immunochemical Analysis of the Teichoic Acid from *Staphylococcus hyicus, ACTA Path. Microbiol. Scan.* 87: 165–69 (1979).
Patrick et al., Defining *Staphylococcus epidermidis* Cell Wall Proteins, *J. Clin. Microbiol.* 28:2757–60 (1990).
Patrick, Coagulase–negative Staphylococci: Pathogens with Increasing Clinical Significance, *J. of Pediatr.* 116: 497–507 (1990).
Plaunt et al., Identification of the Innate Human Immune Response to Surface–Exposed Proteins of Coagulase–Negative Staphylococci, *J. Clin. Microbiol.* 29: 857–61 (1991).
Poole–Warren et al., The Role of Vaccination in the Prevention of Staphylococcal Peritonitis in Continuous Ambulatory Peritoneal Dialysis, *Per. Dial. Int.* 13:176–77 (1993).
Robbins et al., Polysaccharide–Protein Conjugates: A New Generation of Vaccines, *J. Infect. Dis.* 161:821–32 (1990).
Roitt, *Essential Immunology*, Blackwell Scientific Publication, Oxford England, Chap. 4, at 55–68 (1988).
Santos et al., Functional Leukocyte Administration in Protection Against Experimental Neonatal Infection, *Pediatr. Res.* 14: 1408–1410 (1980).
Shaio et al., Effect of Immune Globulin Intravenous on Opsonization of Bacteria by Classic and Alternative Complement Pathways in Premature Serum, *Ped. Res.* 25: 634–40 (1989).
Siber, Immune Globulin to Prevent Nosocomial Infections, *New Eng. J. Med.* 327:269–71 (1992).
Smith et al., Characterization of Cell Envelope Proteins of *Staphylococcus epidermidis* Curtured on Human Perioneal Dialysate, *Infect. & Immun.* 59: 617–24 (1991).
Sutherland, Separation and Purification of Bacterial Antigens, Handbook of Experimental Immunology, 3rd e d., at. 2.1–2.17 (D.M. Weir, ed., 1978).
Takeda et al., Protection against endocarditis due to *Staphylococcus epidermidis* by immunization with capsular polysaccharide/adhesin, *Circulation* 84: 2539–46 (1991).
Thörig et al., Effect of Immunization on the Induction and Course of Experimental *Streptococcus sanguis* and *Staphylococcus epidermidis* Endocarditis, *Infection* 8: 267–74 (1980).
Timmerman et al., Characterization of a Proteinaceous Adhesin of *Staphylococcus epidermidis* which Mediates Attachment to Polystyrene, *Infect & Immun.* 59: 4187–92 (1991).
Timmerman et al., Characterisation and Functional Aspects of Monoclonal Antibodies Specific for Surface Proteins of Coagulase–Negative Staphylococci, *J. Med. Microbiol.* 35: 65–71 (1991).
Tojo et al., Isolation and Characterization of a Capsular Polysaccharide Adhesin from *Staphylococcus epidermidis, J. Infect. Dis.* 157:713–22 (1988).
Van Bronswijk et al., Heterogeneity in Opsonic Requirements of *Staphylococcus epidermidis*: Relative Importance of Surface Hydrophobicity, Capsules and Slime, *Immunol.* 67: 81–86 (1989).
Verbrugh et al., Opsonic Recognition of Staphylococci Mediated by Cell Wall Peptidoglycan: Antibody–Independent Activation of Human Complement and Opsonic Activity of Peptidoglycan Antibodies, *J. Immunol.* 124: 1167–73 (1980).
Verhoef et al., Opsonic Requirements for Staphylococcal Phagocytosis, *Immunology* 33:191–97 (1977).
Verhoef et al., *Staphylococcus epidermidis* Endocarditis and *Staphylococcus epidermidis* Infection in an Intensive Care Unit, *Scand. J. Infect. Dis.* Supp 41: 56–63 (1983).
Wadström, Molecular Aspects of Bacterial Adhesion, Colonization, and Development of Infections Associated with Biomaterials, *J. Invest. Surgery* 2:353–60 (1989).
Wedrén, On Chronic Prostatitis with Special Studies of *Staphylococcus epidermidis, Scand. J. Urololgy & Nephrol.* Supp. 123: 3–36 (1989).
Weisman et al., Intravenous Immune Globulin Prophylaxis on Late–Onset Sepsis in Premature Neonates, *J. Ped.* 125:922–30 (1994).
Wergeland et al., Antibodies to Various Bacterial Cell Wall Peptidoglycans in Human and Rabbit Sera, *J. Clin. Microbiol.* 25: 540–45 (1987).
Wheat, Analysis of Hexosamines in Bacterial Polysaccharides by Chormatographic Procedures, *Methods in Enzymology* 8: 60–78 (1966).
Wilcox et al., Variation in the Expression of Cell Envelope Proteins of Coagulase–Negative Staphylococci Cultured Under Iron–Restricted Conditions in Human Peritoneal Dialysate, *J. Gen. Microbiol.* 137: 2561–70 (1991).

Transferrin
Treatment
Cultured
Peritoneal
Chromatographic

Wilkinson, Immunochemistry of Purified Polysaccharide Type Antigens of Group B Streptococcal Types Ia,Ib, and Ic, *Infect. Immun.* 11: 845–52 (1975).

Williams et al., Protein Antigens of *Staphylococcus epidermidis* Grown Under Iron–Restricted Conditions in Human Peritoneal Dialysate, *FEMS Mircrobiol. Ltrs.* 50:29–33 (1988).

Microbiol.

Yamada et al., Possible Common Biological and Immunological Properties for Detecting Encapsulated Strains of *Staphylococcus epidermidis, J. Clin. Microbiol.* 26:2167–72 (1988).

Yang et al., Mechanisms of Bacterial Opsonization by Immune Globulin Intravenous: Correlation of Complement Consumption with Opsonic Activity and Protective Efficacy, *J. Infect. Dis.* 159:701–07 (1989).

Yoshida et al., Mouse Virulent Strain of *Staphylococcus epidermidis, Jap. J. Microbiol.* 20:209–17 (1976).

Yoshida et al., Staphylococcal Capsular Vaccine for Preventing Mastitis in Two Herds in Georgia, *J. Dairy Sci.* 67: 620–27 (1984).

Yoshida et al., Cross–Protection Between a Strain of *Staphylococcus epidermidis* and Eight Other Species of Coagulase–Negative Staphylococci, *Can. J. Microbiol.* 34:913–15 (1988).

Yoshida et al., Immunological Response to a Strain of *Staphylococcus epidermidis* in the Rabbit: Production of Protective Antibody, *J. Med. Microbiol.* 11: 371–77 (1977).

Yoshida et al., Cross Protection Between an Encapsulated Strain of *Staphylococcus hyicus* and Encapsulated Strains of *Staphylococcus aureus, J. App. Bact.* 65:491–99 (1988).

Yoshitomi, Serological Differentiation of Strains of *Staphylococcus epidermidis* by the Soft Agar Technique, *St. Marianna Med. J.* 17:166–74 (1989).

* cited by examiner

Add:

Yuji, Y. et al. (see PTO-892, pg. 2, Paper No. 14).

Dale et al. (see PTO-892, pg. 2, Paper No. 14).

Ichiman, Y. et al. (see PTO-892, pg. 3, Paper No. 14).

Sutcliffe (see PTO-892, pg. 4, Paper No. 14).

Remington's Pharmaceutical Sciences (see PTO-1449, Jan. 7, 2005).

Sambrook et al. (see PTO-1449, Jan. 7, 2005).

Short Protocols in Molecular Biology (see PTO-1449, Jan. 7, 2005).

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 *(Use several sheets if necessary)*	ATTY. DOCKET NO.: 103901-4199	APPLICATION NO.: 09/893,615
	APPLICANT: Gerald W. FISCHER, et al.	
Sheet 1 of 1	FILING DATE: June 29, 2001	GROUP: 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2003/0235578 A1	12/2003	Stinson et al.			
	A2	2004/0013673 A1	01/2004	Fischer et al.			
	A3	2004/0052779 A1	03/2004	Stinson et al.			

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	C1	Remington's Pharmaceutical Sciences, pp. xv-xvi (A. Gennaro, ed., Mark Publishing Co., 1990)
	C2	Sambrook et al., Molecular Cloning, pp. xi-xxxviii (Cold Spring Harbor Laboratory, 1989)
	C3	Short Protocols in Molecular Biology, pp. iii-xvi (F. Ausubel et al., eds., Greene Publishing Assoc., 1989)

EXAMINER	DATE CONSIDERED 2/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited

Application/Control No.	Applicant(s)/Patent Under Reexam	
09/893,615	Fischer et al	
Examiner	Art Unit	Page 3 of 4
Portner	1645	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Name	Classification[2]	
	A					
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Country	Name	Classification[2]	
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

*		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
x	U	Ichiman Y et al, Microbiol. Immunol. Vol. 33(4), pages 277-286, 1989.
	V	Ichiman, Y et al, Journal of Applied Bacteriology, Vol. 51, pages 229-241, 1981.
x	W	Yoshida, K et al, Journal of Applied Bacteriology, Vol. 65, pages 491-499, 1988.
x	X	Ahmed, A et al, Journal of Applied Bacteriology, Vol. 69, pages 676-685, 1990.

* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a). [1] Dates in MM-YYYY format are publication dates. [2] Classifications may be U.S. or foreign.

Notice of References Cited	Application/Control No. 09/893,615	Applicant(s)/Patent Under Reexam Fischer et al	
	Examiner Portner	Art Unit 1645	Page 2 of 4

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Name	Classification[2]	
x	A	5,505,945	4/1996	Gristina et al	424	164.1
x	B	4,732,757	3/1988	Stolle et al	424	87
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Country	Name	Classification[2]	
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

*		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	Yuji, Y et al, Men'eki Arerugi, Vol. 13(2), pages 50-51, 1994, Figure 4, (abstract only).
	V	Dale, et al, Journal of Infectious Diseases, Vol. 169, apges 319-323, 1994, Passive Protection of Mice against Group A streptococcal Pharyngeal Infection by lipoteichoic acid.
x	W	Endl, J et al, Arch. Microbiol, Sept. 1983, Vol. 135(3), pages 215-223.
x	X	Espersen, F et al, ACTA Pathol, Microbiol. Scand, August 1981, Vol. 80(4), pages 253-260.

* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a). [1] Dates in MM-YYYY format are publication dates. [2] Classifications may be U.S. or foreign.

Notice of References Cited	Application/Control No. 09/893,615	Applicant(s)/Patent Under Reexam Fischer et al	
	Examiner Portner	Art Unit 1645	Page 4 of 4

U.S. PATENT DOCUMENTS

		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Name	Classification[2]	
	A					
	B					
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

		Document Number Country Code-Number-Kind Code	Date MM-YYYY[1]	Country	Name	Classification[2]	
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	U	Sutcliffe, Iain C, Journal of Bacteriology, Vol. 173(22) Nov. 1991, pages 7065-7069.
	V	
	W	
	X	

* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a). [1] Dates in MM-YYYY format are publication dates. [2] Classifications may be U.S. or foreign.